Drummond M F, McGuire A J, Black N A, Petticrew M, McPherson C K
Centre for Health Economics, University of York.
Br J Urol. 1993 Mar;71(3):290-6. doi: 10.1111/j.1464-410x.1993.tb15945.x.
Recent epidemiological studies suggest that much urological disease is untreated. However, the overall economic burden of urological diseases has never been systematically studied. This report estimates the economic burden of treated benign prostatic hyperplasia (BPH) in the United Kingdom by considering the direct costs falling on the health service, the indirect costs in lost production, and the intangible costs in reduced quality of life. Depending on the assumptions made, the economic burden in 1990 is estimated to have been between 62 million pounds and 91 million pounds annually, excluding the intangible costs. The maximum cost to the National Health Service (NHS) represents approximately 0.4% of total NHS expenditure. This finding is therefore consistent with the results of recent epidemiological studies, which suggest that the main burden of BPH is borne by sufferers in terms of reduction in quality of life and is not reflected in consumption of health care resources. However, this balance may change as a result of the new General Practitioner contract and new treatment options.
近期的流行病学研究表明，许多泌尿系统疾病未得到治疗。然而，泌尿系统疾病的总体经济负担从未得到系统研究。本报告通过考虑医疗服务的直接成本、生产损失的间接成本以及生活质量下降的无形成本，估算了英国治疗良性前列腺增生（BPH）的经济负担。根据所做的假设，1990年的经济负担估计每年在6200万英镑至9100万英镑之间，不包括无形成本。国民保健制度（NHS）的最高成本约占NHS总支出的0.4%。因此，这一发现与近期流行病学研究的结果一致，即BPH的主要负担由患者在生活质量下降方面承担，而未反映在医疗保健资源的消耗上。然而，由于新的全科医生合同和新的治疗选择，这种平衡可能会发生变化。
